Hormonal Acne Around the Jawline: Causes and Treatment Options

Hormonal acne along the jawline is acne driven by androgens — hormones like testosterone that push oil glands to produce more sebum, which plugs pores into blackheads, whiteheads and deep cysts. The Cleveland Clinic describes this androgen-driven pattern as typically showing up on the lower cheeks, jawline and chin, and the main treatment options are hormone-directed: oral spironolactone, combined oral contraceptive pills, and the newer topical clascoterone cream.

One correction to the premise first: the jawline is a tendency, not a rule. In a population-based study of adult women published in *Acta Dermato-Venereologica*, acne affected 31.3% of women, and 89.8% of those with acne had it in multiple facial areas — forehead, cheeks, temples and jaw — not the jaw alone. So acne that spreads beyond your jawline can still be hormonal, and acne confined to the jaw is not automatic proof that it is.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What "hormonal" actually means here
Should you be tested for PCOS or another cause?
Spironolactone — what the trial evidence shows
The two limits that decide whether it suits you
Clascoterone, the topical option
Frequently Asked Questions

What "hormonal" actually means here

Androgens are present in everyone. They bind receptors on sebaceous glands, the oil glands sitting alongside each hair follicle, and raise how much sebum those glands pump out. More sebum plus shed skin cells means a plugged follicle — which becomes a comedone, or, deeper down, an inflamed nodule or cyst.

The jawline and chin carry a dense concentration of these glands and appear to respond strongly to androgen signalling, which is why that zone flares when hormones shift. The lesions there tend to be fewer but deeper and more tender than the surface bumps on the forehead — the kind that hurt before they are visible and take weeks to resolve. Importantly, most people with hormonal acne have normal blood hormone levels. The issue is often how sensitive the glands are to ordinary androgen levels, not an excess of androgens, which is why a normal lab panel does not rule hormonal acne out.

Should you be tested for PCOS or another cause?

Acne on its own is not a diagnosis of anything. Under the 2023 international PCOS guideline summarised by Monash University, polycystic ovary syndrome requires two of three Rotterdam features — irregular ovulation, clinical or biochemical androgen excess, and polycystic ovaries on ultrasound. Acne alone meets none of that threshold by itself.

That said, the same guideline treats treatment-resistant acne as a recognised indicator of hyperandrogenism, so persistent jawline acne is a reasonable reason to raise the question with a clinician. It also notes that up to 20% of people with PCOS show no androgen-excess features at all — meaning the absence of acne, hair changes or hair loss does not exclude it either. Signs worth mentioning at an appointment, alongside the acne:.

Irregular, very infrequent or absent periods
New coarse hair growth on the face, chest or abdomen
Scalp hair thinning
Rapid onset of severe acne in an adult with no prior history
Acne that has not responded to standard topical treatment or a course of antibiotics

Spironolactone — what the trial evidence shows

Spironolactone is a blood-pressure drug that also blocks androgen receptors, and dermatologists prescribe it off-label for acne. The American Academy of Dermatology states that when other acne treatments fail, spironolactone effectively treats deep-seated, tender acne on the lower face, jawline or neck — the exact pattern this article is about. It is not prescribed to men, because its anti-androgen side effects are unacceptable for them. The strongest evidence is the SAFA trial, a phase 3 double-blind randomised study in England and Wales reported in the *BMJ* in May 2023.

Women took 50 mg daily for six weeks, escalating to 100 mg if tolerated. Mean Acne-QoL symptom scores reached 21.2 versus 17.4 on placebo — an adjusted difference of 3.45 (95% CI 2.16–4.75), with larger gains at week 24 than week 12 and no serious adverse effects. A systematic review and meta-analysis with trial sequential analysis reached the same conclusion: oral spironolactone gave significant clinical benefit in women with acne without a substantial rise in adverse effects, supporting it as a way to avoid long courses of antibiotics. The AAD's 2024 acne guideline conditionally recommends both spironolactone and combined oral contraceptive pills, and clarifies that potassium monitoring is not needed in healthy patients — only in those with hyperkalemia risk factors such as older age, other conditions, or interacting medications.

The two limits that decide whether it suits you

Timing is the first. Spironolactone needs gradual dose escalation with dermatologist review every four to six weeks at the start, and clearing typically takes six to eight weeks with fuller results at three to six months. That matches the SAFA pattern of better scores at week 24 than week 12. It is a decision about next season, not a fix for a flare before an event this month.

Pregnancy is the second and it is absolute. Fetal exposure to spironolactone can cause serious birth defects, so pregnancy must be avoided while taking it and reliable contraception is required alongside. This is one reason a combined oral contraceptive is sometimes prescribed with it — it covers both requirements at once. Neither limit is a reason to dismiss the drug. They are the two facts to have settled before the appointment, so the conversation starts at dosing rather than eligibility.

Clascoterone, the topical option

Clascoterone 1% cream, sold as Winlevi, is an androgen receptor inhibitor applied to the skin rather than swallowed. It competes with dihydrotestosterone at receptors on the sebaceous glands, blocking the androgen signal locally. The FDA approved it on 27 August 2020 for acne vulgaris in patients aged 12 and older, and it launched in the US in November 2021.

It was the first genuinely new acne mechanism approved in roughly 40 years, backed by two identical double-blind placebo-controlled trials in 1,440 patients that showed lesion reduction at 12 weeks. Because it works at the skin rather than system-wide, it is the one hormonal option not restricted to women. The comparison that matters for a jawline pattern: spironolactone acts throughout the body and has the stronger trial record for deep, tender lower-face lesions, while clascoterone is targeted, avoids systemic anti-androgen effects, and carries the pregnancy and monitoring questions differently. Bring both names to a dermatologist rather than choosing between them from a page — the pregnancy restriction on spironolactone alone can settle it.

Frequently Asked Questions

Does washing my face more often help jawline acne?

No. The problem is androgen-driven sebum production inside the gland, not surface dirt, so scrubbing the area harder does not reach the cause and can inflame already tender lesions.

Can men take spironolactone for jawline acne?

No. The AAD states it is not prescribed for acne in men because of its side effects. Clascoterone cream, approved for patients 12 and older, is the hormonal option that is not sex-restricted.

Do I need regular blood tests on spironolactone?

The AAD's 2024 guideline says potassium monitoring is not needed in healthy patients — only in those with hyperkalemia risk factors such as older age, other medical conditions, or interacting medications. Your prescriber makes that call.

How long before I know whether it is working?

Expect six to eight weeks for clearing to begin and three to six months for fuller results, with dermatologist review every four to six weeks during the initial dose escalation.